scholarly journals Identification of rat T and B lymphocytes by surface marker analysis

1982 ◽  
Vol 16 (1) ◽  
pp. 20-26
Author(s):  
Adelaide W. Koestner ◽  
A. Koestner ◽  
S. Krakowka ◽  
Sue S. Ringler

The majority of thymocytes in suspension (72·1%) formed nonimmune rosettes with guineapig erythrocytes but not with erythrocytes from sheep, cats, dogs, pigs, or man. In contrast, only a minority of cells from lymph node (2·1%) or spleen (1·4%) rosetted with guinea pig erythrocytes. Treatment of guineapig erythrocytes with neuraminidase or 2-S-aminoethyl-isothiouronium bromide did not enhance rosette formation. Adherence of the erythrocytes to tissue sections was achieved in the thymic cortex and T-cell-dependent areas of lymph node and spleen. Absorbed equine anti-rat antithymocyte serum bound 98% thymocytes and 70·0, 35·1 and 44·6% lymphocytes from peripheral blood, spleen and lymph nodes respectively. Surface immunoglobulin was demonstrated on 2·2% thymocytes, 35% peripheral-blood lymphocytes and 43 and 51% cells from lymph nodes and spleen respectively. Complement receptors were determined in suspension with erythrocyte-antibody-complement complexes. Rosetting was observed in 44% splenic, 29% lymph node and 3% thymocyte cellular suspension. The presence of Fc receptors for IgG was assessed by determining the pattern of binding of erythrocyte-antibody complexes to frozen tissue sections. For rats, antithymocyte serum is the method of choice for T cells, whereas SIg determination is the most reliable B-cell marker.

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii89-ii89
Author(s):  
Subhajit Ghosh ◽  
Ran Yan ◽  
Sukrutha Thotala ◽  
Arijita Jash ◽  
Anita Mahadevan ◽  
...  

Abstract BACKGROUND Patients with glioblastoma (GBM) are treated with radiation (RT) and temozolomide (TMZ). These treatments can cause prolonged severe lymphopenia, which is associated with shorter survival. NT-I7 (efineptakin alfa) is a long-acting recombinant human IL-7 that supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. We tested whether NT-I7 would protect T cells from treatment-induced lymphopenia and improve survival. METHODS C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) were treated with RT (1.8 Gy/day x 5 days), TMZ (33 mg/kg/day x 5 days) and/or NT-17 (10 mg/kg on the final day of RT completion). We followed for survival and profiled CD3, CD8, CD4, FOXP3 in peripheral blood over time. In parallel, we assessed cervical lymph nodes, bone marrow, thymus, spleen, and the tumor 6 days after NT-I7 treatment. RESULTS Median survival in mice treated with NT-I7 combined with RT was significantly better than RT alone (GL261: 40d vs 34d, p< 0.0021; CT2A: 90d vs 40d, p< 0.0499) or NT-I7 alone (GL261: 40d vs 24d, p< 0.008; CT2A: 90d vs 32d, p< 0.0154). NT-17 with RT was just as effective as NT-I7 combined with RT and TMZ in both GL261 (40d vs 47d) and CT2A (90d vs 90d). NT-I7 treatment significantly increased the amount of CD8+ cells in the peripheral blood and tumor. NT- I7 rescued CD8+ T cells from RT induced lymphopenia in peripheral blood, spleen, and lymph nodes. NT-I7 alone or NT-I7 in combination with RT increased the CD8+ T cells in peripheral blood and tumor while reducing the FOXP3+ T-reg cells in the tumor microenvironment. CONCLUSIONS NT-I7 protects T-cells from RT induced lymphopenia, improves cytotoxic CD8+ T lymphocytes systemically and in the tumor, and improves survival. Presently, a phase I/II trial to evaluate NT-I7 in patients with high-grade gliomas is ongoing (NCT03687957).


A one-step separation procedure is described for both depleting and obtaining in pure form Fc receptor (FcRL), C'3 receptor (CRL) and surface immunoglobulin bearing (IgL) lymphocytes from rat lymphoid populations. The method is a modification of the Bӧyum (1968) technique for separating lymphocytes from whole blood by sedimentation on Ficoll/Isopaque, and is based on the fact that when a lymphocyte forms a rosette with sensitized erythrocytes it will sediment with the red cells rather than float with the non-rosetting lymphocytes. The technique is > 99.5% efficient at depleting thoracic duct lymphocytes (TDL) of FcRL, CRL and IgL and these subpopulations can be recovered 93-98% pure. The total recovery of lymphocytes applied is usually > 90% and the separated lymphocytes are > 95% viable. This technique allowed the cellular distribution of Fc receptors, C'3 receptors and surface Ig to be determined. It was found that ( a ) Almost all CRL carry surface Ig, although a very small sub-population of CRL (0.2-0.8%) which lacks surface Ig could regularly be detected. ( b ) A substantial proportion of IgL (12-25%) lacks C'3 receptors. ( c ) IgL and CRL which lack Fc receptors are more frequent in spleen and lymph nodes than in TDL. The proportion of this subpopulation increases in TDL after prolonged thoracic duct drainage. ( d ) Some FcRL exist which lack both C'3 receptors and surface Ig. These cells are more evident in TDL after prolonged thoracic duct drainage and in lymph nodes (20-30% of FcRL) than in early TDL or spleen (5-10% of FcRL). ( e ) The thymus contains very few FcRL, CRL or IgL. ( f ) A large population of lymphocytes exists in B rats (32-42% of TDL) which is killed by an anti-B serum but which lacks surface Ig. These cells are much less frequent in normal TDL ( < 5%) and probably also lack Fc and C'3 receptors. ( g ) Large lymphocytes probably shed their Fc and C'3 receptors, but retain their surface Ig, during S-phase. ( h ) Studies on a secondary anti-DNP response showed that a substantial proportion of direct and indirect plaque forming cells (PFC) in the spleen express Fc receptors, whereas only indirect PFC carry C'3 receptors. Virtually all PFC ( > 98%) possess surface Ig.


Blood ◽  
1984 ◽  
Vol 64 (1) ◽  
pp. 166-172 ◽  
Author(s):  
T Machii ◽  
T Kitani

Abstract Six patients with hairy cell leukemia (HCL) were studied for surface immunoglobulin ( sIg ). In all five sIg -positive cases, the heavy chain isotype was IgG. We performed cytologic and cytochemical studies of sIgG + lymphocytes in normal peripheral blood and compared them with hairy cells. Normal sIgM + lymphocytes were also examined. sIgG + and sIgM + lymphocytes made up 0.9% and 6.1% of normal peripheral blood lymphocytes, respectively. Under a phase-contrast microscope, 76% of sIgG + lymphocytes showed cytoplasmic processes similar to those found on hairy cells, whereas most sIgM + lymphocytes had smooth surfaces. Tartrate-resistant acid phosphatase (TRAP) staining revealed that TRAP- positive cells accounted for 65% of sIgG + lymphocytes and 19% of sIgM + lymphocytes. Some (8.3%) of the sIgM + lymphocytes expressed sIgG concomitantly. When sIgM +, sIgM +, sIgG + lymphocytes were excluded, the percentages of cells with surface processes and of TRAP-positive cells in the remaining sIgM +, sIgG - lymphocytes were 10% and 12%, respectively. A very small proportion (0.2%) of sIgM -, sIgG - lymphocytes had cytoplasmic processes. These results indicate that normal sIgG + lymphocytes are cytologically and cytochemically different from most sIgM + lymphocytes and that the phase-contrast microscopic appearances and TRAP activity of sIgG + lymphocytes are similar to those of HCL tumor cells.


Blood ◽  
1993 ◽  
Vol 82 (7) ◽  
pp. 2143-2151 ◽  
Author(s):  
JC Reubi ◽  
B Waser ◽  
U Horisberger ◽  
E Krenning ◽  
SW Lamberts ◽  
...  

Abstract Receptors for the neuropeptide somatostatin (SS) were evaluated in vitro and in vivo in various human lymphatic tissues, ie, thymus, spleen, and lymph nodes; thymic carcinoids and thymomas were also tested. The receptors were measured in vitro using receptor autoradiography on tissue sections incubated with the SS analog 125I- [Tyr3]-octreotide or 125I-[Leu8,D-Trp22,Tyr25]-SS-28. All tissues were SS-receptor positive for either radioligand, except the thymomas. In thymic tissue, the receptors were diffusely located in the medulla, presumably on epithelial cells. In the spleen, the red pulp was strongly labeled. In the lymph nodes, the germinal centers were preferentially labeled. In all tissues, the receptors were of high affinity (kd thymus, 0.84 nmol/L; kd spleen, 1.6 nmol/L; kd lymph node, 0.62 nmol/L) and specific for SS. Displacement by nanomolar concentrations of SS-14, SS-28, and octreotide was observed, as was guanosine triphosphate dependency. The in vivo visualization of somatostatin receptors was performed after injection of 111In-DTPA- octreotide and gamma-camera scintigraphy. The spleen, but not thymus or lymph nodes, were visualized. These data suggest an important role for SS in regulating immune functions through SS receptors in thymus, spleen, and lymph nodes. Furthermore, SS may regulate neuroendocrine functions in the thymus.


1968 ◽  
Vol 128 (6) ◽  
pp. 1437-1449 ◽  
Author(s):  
David M. Lubaroff ◽  
Byron H. Waksman

The precise origin of cells infiltrating tuberculin skin reactions was studied with the technique of immunofluorescence. Thymectomized, irradiated Lewis rats were restored with bone marrow from allogeneic or F1 donors. They were passively sensitized to tuberculin by a subsequent transfer of Lewis lymph node cells and were given intradermal skin tests with tuberculoprotein. In 24 hr reactions the majority of cells were shown to be derived from the infused marrow. These results were the same regardless whether the lymphocyte transfer was performed on the day of irradiation and marrow injection or 7 days later. The cells in the tuberculin reactions, marrow, spleen, and lymph nodes not derived from the bone marrow were found to originate in the transferred lymph node cells. The relative percentages of marrow-derived and lymph node-derived cells in the tuberculin reactions remained the same during the 9–24 hr period following skin test.


Blood ◽  
1972 ◽  
Vol 40 (3) ◽  
pp. 303-310 ◽  
Author(s):  
Seth Pincus ◽  
Celso Bianco ◽  
Victor Nussenzweig

Abstract In the present study we present evidence that the proportion of complement-receptor lymphocytes (CRL) is greatly increased in the circulation in most cases of chronic lymphocytic leukemia (CLL). Lymphocytes (&gt; 99% pure, 70% recovery) were obtained from the peripheral blood of normal individuals by separation of the mononuclear cells from the leukocyte-enriched plasma by differential flotation in Hypaque-Ficoll and incubation of the mononuclear cells with iron-containing particles followed by removal of the phagocytes with a magnet. Complement - receptor lymphocytes were detected by incubating lymphocytes with sheep erythrocytes coated with antibody and mouse complement (EAC) and counting the EAC—CRL rosettes under the microscope. 7.1 ± 3.8% of normal peripheral blood lymphocytes, 31.0 ± 6.9% of lymph node, and 59.6 ± 13.2% of tonsil lymphocytes bind EAC. The binding was C3-dependent since it could be inhibited specifically by papain fragments of rabbit antibodies to mouse C3. Among lymphocytes from the peripheral blood of patients with CLL, 50.7 ± 25.0% bear the complement receptor. These results suggest that CLL preferentially affects B cells.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 647-647
Author(s):  
David T. Teachey ◽  
Alix Seif ◽  
Junior Hall ◽  
Theresa Ryan ◽  
Gregor Reid ◽  
...  

Abstract Patients and mice with both the autoimmune lymphoproliferative syndrome (ALPS) and systemic lupus erythematosis (SLE) have T cell dysregulation and produce both abnormal, activated T lymphocytes and an unusual T cell population, Double Negative T cells (DNTs, cell phenotype: CD3+, CD4-, CD8-, TCR αβ+). The Notch signaling pathway is important in T cell lineage development, including development of DNTs, and in T cell activation. Inhibitors of this pathway are in clinical development, because inhibiting Notch signaling may be effective in treating Alzheimer’s disease and T cell leukemia. We hypothesized that inhibiting Notch signaling would be effective in reducing symptoms and treating the disease in patients with ALPS and SLE by both reducing the production of abnormal DNTs and by blocking aberrant T cell activation. We tested this hypothesis using two murine models of defective lymphocyte apoptosis, CBA-lprcg and MRL-lpr. CBA-lprcg has a phenotype similar to human ALPS, as these mice develop massive lymphadenopathy and splenomegaly with DNT infiltration of these organs. In the MRL-lpr background, the apoptotic defect manifests itself in a phenotype similar to human SLE, as these mice develop autoantibodies, glomerulonephritis, and a vasculitic dermatitis. Mice were randomized to treatment with a low dose (5mg/kg/day) of the α-secretase inhibitor, DAPT, for 5 days a week by gavage versus vehicle. Treatment response was followed with assessment of DNTs in peripheral blood and lymphoid tissue by flow cytometry, by monitoring of lymph node and spleen size with small animal ultrasound, and ELISA to quantify antibody titer for anti-dsDNA IgG specific antibodies. We found a profound and statistically significant decrease in antibody titer (p = 0.02), lymphadenopathy (p = 0.006), and splenomegaly (p = 0.008) after only 4 weeks, comparing mice treated with DAPT to control animals (Table). Treated mice also had decreased absolute DNTs in their spleens (p = 0.02) and lymph nodes (p = 0.04) compared to control. Treated mice had a trend toward decreased absolute DNTs in peripheral blood; however, more animals are being enrolled on this study to reach 80% power to detect a statistically significant difference. Finally, treated MRL-lpr mice showed stabilization or improvement in their characteristic vasculitic skin disease, whereas control animals showed progression. We found the response to DAPT was durable, having treated mice for over 12 weeks. Also, with this dosing schema, mice experienced no toxicity. They did not manifest any gastrointestinal symptoms, as have been reported with other γ-secretase inhibitors. In summary, inhibiting the Notch signaling pathway appears to be a safe and well-tolerated means of treating autoimmune and lymphoproliferative diseases. This is the first report to use γ-secretase inhibitors to treat non-malignant, T-lymphocyte mediated disease. Disease Parameter(1) DAPT Treated(2) Vehicle Control(2) p value (1) Averge antibody titer, volume of lymph nodes, and area of spleens were similar and not statistically different between groups at initiation of treatment; (2) average (range) after 4 weeks of treatment Lymph node volume by ultrasound (mm3) 360 (170–550) 780 (366–1043) p = 0.006 Splenic area by ultrasound (mm2) 48 (27–73) 159 (69–336) p = 0.008 anti-dsDNA IgG antibody titer (ug/ml) 450 (340–560) 1350 (1260–1410) p = 0.02


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 692-692
Author(s):  
Matthew S. Davids ◽  
Jennifer R. Brown ◽  
Adrian Wiestner ◽  
Anthony G. Letai

Abstract Abstract 692 Treatments for chronic lymphocytic leukemia (CLL) often kill malignant cells in the peripheral blood, but the disease inevitably relapses in the lymph nodes or bone marrow. BH3 profiling was developed in our laboratory to assess the degree to which malignant cells are primed to undergo apoptosis by the mitochondrial pathway, and to identify the anti-apoptotic proteins on which these cells depend for their survival. We hypothesized that BH3 profiling can help elucidate mechanisms underlying stromal-mediated resistance to the BH3-mimetic ABT-737 in CLL. BH3 profiling was performed by exposing malignant CD19+ B cells from 15 CLL patients to a panel of BH3-domain peptides, and the cell death induced was quantified by JC-1 based FACS to assess mitochondrial outer membrane permeabilization, as previously described (Ryan et al., PNAS 2010). To simulate lymph node and bone marrow microenvironments, we co-cultured CLL cells from a subset of these patients for 24 hours in the presence of IL-4 with CD154+ fibroblasts and with HS5 cells, respectively, and then repeated BH3 profiling. The status of the chemokine receptor CXCR4, which can serve as a marker for the residence of CLL cells in stromal microenvironments, was also evaluated by FACS. Additional co-culture experiments were done in the presence or absence of ABT-737 at 100 nM, and CLL cell viability was assessed at 24 hours by Annexin-PI. We also performed BH3 profiling on 7 additional CLL patients with matched peripheral blood, lymph node, and bone marrow samples. Circulating malignant CLL cells were highly primed to undergo apoptosis, and their survival was mainly dependent on Bcl-2, and to a lesser degree Mcl-1. CXCR4 decreased on CLL cells co-cultured for 24 hours with CD154+ fibroblasts (38.6%) compared to cells cultured with parental controls (76.3%) (p = 0.030), but did not decrease on cells cultured with HS5 cells (87.1%) (p > 0.05). When CLL cells were co-cultured with CD154+ fibroblasts in the presence of ABT-737, mean CLL cell viability by Annexin-PI increased to 85.1% compared to 31.8% (p < 0.001) in cells co-cultured with parental controls. BH3 profiling revealed that CD154+ fibroblast exposure led to decreased CLL cell mitochondrial depolarization in response to Bim, Noxa, Hrk, and particularly to ABT-737 (see figure). In contrast, CLL cells exposed to HS5 cells had unchanged CXCR4 status, but still had a decrease in apoptotic priming, which was observed in response to an even broader range of BH3-domain peptides, including Puma and Bmf. When gating on the whole CLL cell population, the pattern and degree of apoptotic priming was similar in matched peripheral blood, lymph node, and bone marrow biopsy samples from 7 additional patients. Interestingly, gating on CXCR4 status revealed heterogeneity in apoptotic priming in the different microenvironments, with a subset of patients showing that CXCR4- bone marrow-derived CLL cells were less primed than their CXCR4+ counterparts. Overall, BH3 profiling demonstrated that circulating primary CLL cells are highly primed to undergo apoptosis, and depend predominantly on the anti-apoptotic protein Bcl-2 for their survival. CLL cells co-cultured with lymph node-like stroma had decreased CXCR4 surface expression and became resistant to ABT-737. BH3 profiling demonstrated that this resistance was accompanied by decreased apoptotic priming in response to several BH3-domain peptides. An even broader decrease in apoptotic priming was observed in response to co-culture with a bone marrow-like microenvironment, apparently unrelated to changes in CXCR4 status. Matched peripheral blood, lymph node, and bone marrow CLL patient samples had similar BH3 profiles overall, but some patients showed decreased apoptotic priming in CXCR4- CLL cells, which likely represent the true bone marrow resident CLL cell population. This heterogeneity in mitochondrial priming may help to explain some of the resistance to therapy observed in bone marrow and lymph nodes as compared to peripheral blood. Disclosures: Letai: Eutropics Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees.


Sign in / Sign up

Export Citation Format

Share Document